Investment announcementsPublished on Jun 3, 2025
MEDTECH

Transforming Chronic Wound Care with GelSana Therapeutics

Improving Healing with Advanced Hydrogel Technology

Ayah Hamdan and Karlens Joas

A Better Solution for Chronic Wound Care

Chronic wounds, such as diabetic ulcers, are a major issue in healthcare. These wounds are slow to heal and often lead to complications like infections, longer hospital stays, and amputations in severe cases. Traditional wound care methods are not always effective and require frequent dressing changes, which cause discomfort for patients and are time-consuming for healthcare providers.

GelSana Therapeutics, based in Aurora, Colorado, is tackling this problem with Cleragel, a hydrogel dressing designed to speed up the healing process. Cleragel uses a unique polymer technology that reduces inflammation, fights infection, and delivers medication slowly to the wound. This technology reduces the need for frequent dressing changes, helping patients heal faster and reducing hospital costs while improving patient comfort.

Cleragel works by creating a moist, protective layer around the wound, which helps the tissue heal more quickly. Unlike traditional dressings, Cleragel stays in place longer, which means fewer changes are needed. This helps reduce the pain and inconvenience of frequent dressing changes, making the healing process more efficient and comfortable for patients.

The hydrogel also helps reduce inflammation and protect against infection, two common challenges in wound healing. By addressing these issues, Cleragel supports faster recovery, fewer complications, and better overall results for patients. The slow release of treatment from the hydrogel ensures the wound continues to heal without needing constant attention.

Why Is This Problem Significant, & How Large Is Its Impact?

Chronic wounds affect millions of people, especially those with diabetes. In the U.S. alone, more than 6.7 million people suffer from chronic wounds, which lead to infections, longer stays in hospitals, and in some cases, amputations. These wounds also put a huge strain on healthcare systems, costing more than $50 billion globally each year.

Current treatments for chronic wounds often do not work well enough and require regular dressing changes, which can be painful for patients and costly for hospitals. As the number of people with diabetes and other chronic conditions grows, the demand for better treatments is becoming even more urgent.

GelSana Therapeutics is addressing this need with Cleragel, a solution that helps heal wounds more quickly, prevents infections, and reduces the need for frequent dressing changes, which improves the overall patient experience.

Meet the Team Behind GelSana

GelSana Therapeutics is led by a team that brings together scientific expertise and business experience.

  • Dr. Melissa Krebs (Founder & CEO): Dr. Krebs is an Associate Professor at Colorado School of Mines and an expert in hydrogel technology. Her research in wound healing led to the creation of Cleragel. She founded GelSana to apply her research in real-world healthcare, aiming to improve the healing process for patients with chronic wounds.
  • Jon Fernandez (COO): Jon has a strong background in business, having held leadership roles at Johnson & Johnson and Franklin Group. His experience in launching and scaling medical products is key to GelSana's growth, as they work toward getting FDA approval and reaching more markets.

Together, they lead a focused team dedicated to improving the care of patients with chronic wounds. Their combined knowledge and commitment to innovation are driving GelSana’s progress in the wound care field.

undefined

Founder and CEO

Melissa Krebs

Why We’re Excited to Invest

We are excited to support GelSana Therapeutics because their solution, Cleragel, represents a major improvement over current wound care methods. By reducing the need for frequent dressing changes and promoting faster healing, Cleragel offers a more comfortable and cost-effective treatment for patients and healthcare providers.

 

With strong scientific research and a leadership team with commercial expertise, GelSana is in a great position for future growth. Their approach addresses a significant need in wound care and has the potential to make a real difference in the lives of millions of patients.

 

We look forward to supporting GelSana as they continue to grow and make an impact in healthcare.
 

 



Plug and Play is one of the most active VCs in Silicon Valley. Our goal is to fund the teams building the defensible businesses of the future. Join our ecosystem today.